Drug intelligence / Profile preview

TV-48108

Development stage: Discontinued
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Inhalation

Overview

TV-48108 is a small molecule drug that was developed by Teva Pharmaceutical Industries for the treatment of respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). It was formulated as an inhaled bronchodilator. The precise mechanism of action has not been defined in public sources. Development reached phase 1 clinical trials but was ultimately discontinued[2][3][4].

Other names: TV 48108TV48108TV-48108TEV 48108TEV48108TEV-48108

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on TV-48108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV-48108.

Explore the full profile